Together, these findings support that integrin-mediated mTOR signaling drives TGF-β overactivation, inflammation, and myxomatous mitral valve degeneration, and we propose mTOR inhibition as a possible medical therapy for MVP. This evidence concerns the gene MTOR and familial mitral valve prolapse.